Synergia Medical SA, a Mont-Saint-Guibert, Belgium-based opto-electronics developer advancing medical devices for neurostimulation, raised €8.1m in Series A funding.
The round was led by new investor Newton Biocapital with participation from new investors Financière Spin-off Luxembourgeoise and Belgian regional growth funds SRIW (Société Régionale d’Investissement de Wallonie) and SFPI-FPIM (Belgian Federal Holding and Investment Company).
The company intends to use the funds to bring its vagus nerve stimulation device NAOS through final testing prior to CE mark submission.
Founded in 2013 by Pascal Doguet and Attila Borbath, Synergia Medical is an opto-electronics developer focused on medical devices for neurostimulation. Its lead product, NAOS, is a small-form, MRI-safe, implanted neurostimulation device for drug-resistant epilepsy, with a range of further therapeutic applications. The company is conducting advanced-stage testing of the device ahead of CE mark filing expected in 2019. Synergia will also prepare for regulatory approval in the United States where neurostimulation is increasingly prevalent.
In association with the financing, Synergia has also appointed Reinhard Krickl as its Board of Directors’ Chairman, and Guy Heynen MD of Newton Biocapital and Pierre Detrixhe of Financière Spin-off Luxembourgeoise as Non-Executive Directors.